Unknown

Dataset Information

0

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.


ABSTRACT:

Background

Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC.

Summary

In this systematic review and individual patient data meta-analysis of randomized-controlled trials (RCTs), we searched MEDLINE and Embase from inception till September 2022 for RCTs that provided data for overall survival (OS) and progression-free survival (PFS) for sorafenib monotherapy as first-line systemic therapy for advanced HCC. We performed a pooled analysis using reconstructed individual participant data from published Kaplan-Meier curves to obtain robust estimates for OS and PFS. Of 1,599 articles identified, 29 studies (5,525 patients) met the inclusion criteria. Overall, the median OS was 10.4 (95% CI: 9.6-11.4) months. Median OS increased over time, from 9.8 (95% CI: 8.8-10.7) months in studies before 2015 to 13.4 (95% CI: 11.03-15.24) months in studies from 2015 onwards (p < 0.001). OS did not differ by trial phase, geographical region, or study design. The overall median PFS was 4.4 (95% CI: 3.9-4.8) months, but PFS did not improve over time. Sensitivity analysis of studies from 2015 and onwards to account for the introduction of direct-acting antivirals determined that hepatitis C virus was associated with reduced mortality (p < 0.001). There was minimal heterogeneity in the estimates for OS (all I2 ≤ 33).

Key messages

Survival outcomes for sorafenib in advanced HCC have improved over time. These data have important implications for clinical trial design.

SUBMITTER: Tan DJH 

PROVIDER: S-EPMC10601853 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC.<h4>Summary</h4>In this systematic review and individual patient data meta-analysis of randomized-controlled trials (RCTs), we searched MEDLINE and Embase from inception till September 2022 for RCTs that provided data for overall survival (OS) an  ...[more]

Similar Datasets

| S-EPMC9021659 | biostudies-literature
| S-EPMC5332836 | biostudies-literature
| S-EPMC5016063 | biostudies-literature
| S-EPMC7205300 | biostudies-literature
| S-EPMC4918283 | biostudies-literature
| S-EPMC6679028 | biostudies-literature
| S-EPMC3989951 | biostudies-literature
| S-EPMC5385412 | biostudies-literature
| S-EPMC4251972 | biostudies-literature
| S-EPMC11291229 | biostudies-literature